Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold

Virology

Volumn 405, Issue 2, 2010, Pages 513-523

  Totrov, Maxim ^a   Jiang, Xunqing ^c   Kong, Xiang Peng ^c   Cohen, Sandra ^c   Krachmarov, Chavdar ^d   Salomon, Aidy ^d   Williams, Constance ^c   Seaman, Michael S ^e   Cardozo, Timothy ^c   Gorny, Miroslaw K ^c   Wang, Shixia ^f   Lu, Shan ^f   Pinter, Abraham ^d   Zolla Pazner, Susan ^b,c  

^a MOLSOFT LLC   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

447 52D; Cholera toxin B subunit; Gp120; HIV vaccine; HIV 1; Immunogen design; Neutralizing antibody; V3 loop

Indexed keywords

CHOLERA TOXIN B SUBUNIT; DNA; DNA VACCINE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BINDING AFFINITY; CONFORMATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RABBIT; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CHOLERA TOXIN; DRUG DESIGN; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; IMMUNIZATION; PEPTIDE FRAGMENTS; RABBITS;

HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS;

EID: 77955657135     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.06.027     Document Type: Article

References (87)

1. Abagyan R., Totrov M. Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. J. Mol. Biol. 1994, 235:983-1002.
2. Abagyan R., Totrov M., Kuznetsov D. ICM-a new method for protein modelling and design. Applications to docking and structure prediction from the distorted native conformation. J. Comp. Chem. 1994, 15:488-506.
3. Albritton L.M., Kim J.W., Tseng L., Cunningham J.M. Envelope-binding domain in the cationic amino acid transporter determines the host range of ecotropic murine retroviruses. J. Virol. 1993, 67:2091-2096.
4. Backstrom M., Lebens M., Schodel F., Holmgren J. Insertion of a HIV-1-neutralizing epitope in a surface-exposed internal region of the cholera toxin B-subunit. Gene 1994, 149:211-217.
5. Barnett S.W., Lu S., Srivastava I., Cherpelis S., Gettie A., Blanchard J., Wang S., Mboudjeka I., Leung L., Lian Y., Fong A., Buckner C., Ly A., Hilt S., Ulmer J., Wild C.T., Mascola J.R., Stamatatos L. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J. Virol. 2001, 75:5526-5540.
6. Barouch D.H. Challenges in the development of an HIV-1 vaccine. Nature 2008, 455:613-619.
7. Backstrom M., Holmgren J., Schodel F., Lebens M. Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli. Gene 1995, 165:163-171.
8. Bell C.H., Pantophlet R., Schiefner A., Cavacini L.A., Stanfield R.L., Burton D.R., Wilson I.A. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. J. Mol. Biol. 2008, 375:969-978.
9. Bergmann C., Stohlmann S.A., McMillan M. An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein. Eur. J. Immunol. 1993, 23:2777-2781.
10. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 2004, 78:13232-13252.
11. Bui H.H., Sidney J., Peters B., Sathiamurthy M., Sinichi A., Purton K.A., Mothe B.R., Chisari F.V., Watkins D.I., Sette A. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics 2005, 57:304-314.
12. Burke V., Williams C., Sukumaran M., Kim S.S., Li H., Wang X.H., Gorny M.K., Zolla-Pazner S., Kong X.P. Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens. Structure 2009, 17:1538-1546.
13. Cardozo T., Kimura T., Philpott S., Weiser B., Burger H., Zolla-Pazner S. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res. Hum. Retroviruses 2007, 23:415-426.
14. Chan D.C., Fass D., Berger J.M., Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89:263-273.
15. Corti D., Langedijk J.P., Hinz A., Seaman M.S., Vanzetta F., Fernandez-Rodriguez B.M., Silacci C., Pinna D., Jarrossay D., Balla-Jhagjhoorsingh S., Willems B., Zekveld M.J., Dreja H., O'Sullivan E., Pade C., Orkin C., Jeffs S.A., Montefiori D.C., Davis D., Weissenhorn W., McKnight A., Heeney J.L., Sallusto F., Sattentau Q.J., Weiss R.A., Lanzavecchia A. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 2010, 5:e8805.
16. Cruz L.J., Iglesias E., Aguilar J.C., Cabrales A., Reyes O., Andreu D. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1. Bioconjug. Chem. 2004, 15:1110-1117.
17. Cruz L.J., Iglesias E., Aguilar J.C., Gonzalez L.J., Reyes O., Albericio F., Andreu D. A comparative study of different presentation strategies for an HIV peptide immunogen. Bioconjug. Chem. 2004, 15:112-120.
18. Czerkinsky C., Russell M.W., Lycke N., Lindblad M., Holmgren J. Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. Infect. Immun. 1989, 57:1072-1077.
19. Davis K.L., Bibollet-Ruche F., Li H., Decker J.M., Kutsch O., Morris L., Salomon A., Pinter A., Hoxie J.A., Hahn B.H., Kwong P.D., Shaw G.M. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J. Virol. 2009, 83:1240-1259.
20. Dhillon A.K., Stanfield R.L., Gorny M.K., Williams C., Zolla-Pazner S., Wilson I.A. Structure determination of an anti-HIV-1 Fab 447-52D-peptide complex from an epitaxially twinned data set. Acta Crystallogr. D Biol. Crystallogr. 2008, D64:792-802.
21. Eckhart L., Raffelsberger W., Ferko B., Klima A., Purtscher M., Katinger H., Ruker F. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J. Gen. Virol. 1996, 77(Pt 9):2001-2008.
22. Eriksson K., Fredriksson M., Nordstrom I., Holmgren J. Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development. Infect. Immun. 2003, 71:1740-1747.
23. Francis D.P., Heyward W.L., Popovic V., Orozco-Cronin P., Orelind K., Gee C., Hirsch A., Ippolito T., Luck A., Longhi M., Gulati V., Winslow N., Gurwith M., Sinangil F., Berman P.W. Candidate HIV/AIDS vaccines: lessons learned from the world's first phase III efficacy trials. AIDS 2003, 17:147-156.
24. Gonzalez R.A., Sanchez J., Holmgren J., Lopez S., Arias C.F. Immunological characterization of a rotavirus-neutralizing epitope fused to the cholera toxin B subunit. Gene 1993, 133:227-232.
25. Gorny M.K., Revesz K., Williams C., Volsky B., Louder M.K., Anyangwe C.A., Krachmarov C., Kayman S.C., Pinter A., Nadas A., Nyambi P.N., Mascola J.R., Zolla-Pazner S. The V3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J. Virol. 2004, 78:2394-2404.
26. Gorny M.K., VanCott T.C., Hioe C., Israel Z.R., Michael N.L., Conley A.J., Williams C., Kessler J.A., Chigurupati P., Burda S., Zolla-Pazner S. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. J. Immunol. 1997, 159:5114-5122.
27. Gorny M.K., Williams C., Volsky B., Revesz K., Cohen S., Polonis V.R., Honnen W.J., Kayman S.C., Krachmarov C., Pinter A., Zolla-Pazner S. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J. Virol. 2002, 76:9035-9045.
28. Gorny M.K., Williams C., Volsky B., Revesz K., Wang X.H., Burda S., Kimura T., Konings F.A., Nadas A., Anyangwe C.A., Nyambi P., Krachmarov C., Pinter A., Zolla-Pazner S. Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1. J. Virol. 2006, 80:6865-6872.
29. Gorny M.K., Xu J.Y., Karwowska S., Buchbinder A., Zolla-Pazner S. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 1993, 150:635-643.
30. Hanke T., Goonetilleke N., McMichael A.J., Dorrell L. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J. Gen. Virol. 2007, 88:1-12.
31. Hill C.M., Deng H., Unutmaz D., Kewalramani V.N., Bastiani L., Gorny M.K., Zolla-Pazner S., Littman D.R. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. J. Virol. 1997, 71:6296-6304.
32. Hioe C.E., Visciano M.L., Kumar R., Liu J., Mack E.A., Simon R.E., Levy D.N., Tuen M. The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120. Vaccine 2009, 28:352-360.
33. Hioe C.E., Wrin T., Seaman M.S., Yu X., Wood B., Self S., Williams C., Gorny M.K., Zolla-Pazner S. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes. PLoS ONE 2010, 5:e10254.
34. Honnen W.J., Krachmarov C., Kayman S.C., Gorny M.K., Zolla-Pazner S., Pinter A. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence. J. Virol. 2007, 81:1424-1432.
35. Huang C.C., Tang M., Zhang M.Y., Majeed S., Montabana E., Stanfield R.L., Dimitrov D.S., Korber B., Sodroski J., Wilson I.A., Wyatt R., Kwong P.D. Structure of a V3-containing HIV-1 gp120 core. Science 2005, 310:1025-1028.
36. Jiang, X., Burke, V., Totrov, M., Williams, C., Cardozo, T., Gorny, M.K., Zolla-Pazner, C., Kong, X.-P. in press. Conserved structural elements in the V3 Crown of HIV-1 gp120 Nat. Struct. Mol. Biol.
37. Kayman S.C., Wu Z., Revesz K., Chen H., Kopelman R., Pinter A. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains. J. Virol. 1994, 68:400-410.
38. Krachmarov C., Pinter A., Honnen W.J., Gorny M.K., Nyambi P.N., Zolla-Pazner S., Kayman S.C. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B V3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. J. Virol. 2005, 79:780-790.
39. Krachmarov C.P., Honnen W.J., Kayman S.C., Gorny M.K., Zolla-Pazner S., Pinter A. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. J. Virol. 2006, 80:7127-7135.
40. Krachmarov C.P., Kayman S.C., Honnen W.J., Trochev O., Pinter A. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 2001, 17:1737-1748.
41. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., Steenbeke T.D., Venturi M., Chaiken I., Fung M., Katinger H., Parren P.W., Robinson J., Van Ryk D., Wang L., Burton D.R., Freire E., Wyatt R., Sodroski J., Hendrickson W.A., Arthos J. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002, 420:678-682.
42. Kwong P.D., Wyatt R., Majeed S., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 2000, 8:1329-1339.
43. Labrosse B., Treboute C., Brelot A., Alizon M. Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor. J. Virol. 2001, 75:5457-5464.
44. Lasky L.A., Groopman J.E., Fennie C.W., Benz P.M., Capon D.J., Dowbenko D.J., Nakamura G.R., Nunes W.M., Renz M.E., Berman P.W. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science 1986, 233:209-212.
45. Law M., Cardoso R.M., Wilson I.A., Burton D.R. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J. Virol. 2007, 81:4272-4285.
46. HIV Sequence Compendium 2005, Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, LA-UR 06-0680. T. Leitner, F.B., B. Hahn, P. Marx, F. McCutchan, J. Mellors, S. Wolinsky, B. Korber (Eds.).
47. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 2005, 79:10108-10125.
48. Lipscombe M., Charles I.G., Roberts M., Dougan G., Tite J., Fairweather N.F. Intranasal immunization using the B subunit of the Escherichia coli heat-labile toxin fused to an epitope of the Bordetella pertussis P.69 antigen. Mol. Microbiol. 1991, 5:1385-1392.
49. Liu J., Bartesaghi A., Borgnia M.J., Sapiro G., Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008, 455:109-113.
50. Lopez-Gigosos R., Garcia-Fortea P., Reina-Dona E., Plaza-Martin E. Effectiveness in prevention of travellers' diarrhoea by an oral cholera vaccine WC/rBS. Travel Med. Infect. Dis. 2007, 5:380-384.
51. Martin M., Hajishengallis G., Metzger D.J., Michalek S.M., Connell T.D., Russell M.W. Recombinant antigen-enterotoxin A2/B chimeric mucosal immunogens differentially enhance antibody responses and B7-dependent costimulation of CD4(+) T cells. Infect. Immun. 2001, 69:252-261.
52. Matoba N., Geyer B.C., Kilbourne J., Alfsen A., Bomsel M., Mor T.S. Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR (649-684), a mucosal subunit HIV/AIDS vaccine candidate. Vaccine 2006, 24:5047-5055.
53. Matthews T.J., Langlois A.J., Robey W.G., Chang N.T., Gallo R.C., Fischinger P.J., Bolognesi D.P. Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:9709-9713.
54. Mbah H.A., Burda S., Gorny M.K., Williams C., Revesz K., Zolla-Pazner S., Nyambi P.N. Effect of soluble CD4 on exposure of epitopes on primary, intact, native human immunodeficiency virus type 1 virions of different genetic clades. J. Virol. 2001, 75:7785-7788.
55. McBurney S.P., Ross T.M. Viral sequence diversity: challenges for AIDS vaccine designs. Expert Rev. Vaccin. 2008, 7:1405-1417.
56. McKenzie S.J., Halsey J.F. Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response. J. Immunol. 1984, 133:1818-1824.
57. Merritt E.A., Kuhn P., Sarfaty S., Erbe J.L., Holmes R.K., Hol W.G. The 1.25 Å resolution refinement of the cholera toxin B-pentamer: evidence of peptide backbone strain at the receptor-binding site. J. Mol. Biol. 1998, 282:1043-1059.
58. Merritt E.A., Sarfaty S., Jobling M.G., Chang T., Holmes R.K., Hirst T.R., Hol W.G. Structural studies of receptor binding by cholera toxin mutants. Protein Sci. 1997, 6:1516-1528.
59. Muster T., Guinea R., Trkola A., Purtscher M., Klima A., Steindl F., Palese P., Katinger H. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 1994, 68:4031-4034.
60. Nielsen M., Lundegaard C., Lund O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinform. 2007, 8:238.
61. Nyambi P., Burda S., Urbanski M., Heyndrickx L., Janssens W., Vanham G., Nadas A. Neutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals. AIDS Res. Hum. Retroviruses 2008, 24:1507-1519.
62. Pantophlet R., Aguilar-Sino R.O., Wrin T., Cavacini L.A., Burton D.R. Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology 2007, 364:441-453.
63. Pantophlet R., Wrin T., Cavacini L.A., Robinson J.E., Burton D.R. Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity. Virology 2008, 381:251-260.
64. Parren P.W., Burton D.R., Sattentau Q.J. HIV-1 antibody-debris or virion?. Nat. Med. 1997, 3:366-367.
65. Parren P.W., Gauduin M.C., Koup R.A., Poignard P., Fisicaro P., Burton D.R., Sattentau Q.J. Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. Immunol. Lett. 1997, 57:105-112.
66. Peters B., Sidney J., Bourne P., Bui H.H., Buus S., Doh G., Fleri W., Kronenberg M., Kubo R., Lund O., Nemazee D., Ponomarenko J.V., Sathiamurthy M., Schoenberger S.P., Stewart S., Surko P., Way S., Wilson S., Sette A. The design and implementation of the immune epitope database and analysis resource. Immunogenetics 2005, 57:326-336.
67. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., Benenson M., Gurunathan S., Tartaglia J., McNeil J.G., Francis D.P., Stablein D., Birx D.L., Chunsuttiwat S., Khamboonruang C., Thongcharoen P., Robb M.L., Michael N.L., Kunasol P., Kim J.H. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361:2209-2220.
68. Scheid J.F., Mouquet H., Feldhahn N., Seaman M.S., Velinzon K., Pietzsch J., Ott R.G., Anthony R.M., Zebroski H., Hurley A., Phogat A., Chakrabarti B., Li Y., Connors M., Pereyra F., Walker B.D., Wardemann H., Ho D., Wyatt R.T., Mascola J.R., Ravetch J.V., Nussenzweig M.C. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009, 458:636-640.
69. Seaman M.S., Leblanc D.F., Grandpre L.E., Bartman M.T., Montefiori D.C., Letvin N.L., Mascola J.R. Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. Virology 2007, 367:175-186.
70. Sharon M., Kessler N., Levy R., Zolla-Pazner S., Gorlach M., Anglister J. Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure 2003, 11:225-236.
71. Shioda T., Levy J.A., Cheng-Mayer C. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:9434-9438.
72. Stanfield R.L., Gorny M.K., Williams C., Zolla-Pazner S., Wilson I.A. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure 2004, 12:193-204.
73. Stanfield R.L., Gorny M.K., Zolla-Pazner S., Wilson I.A. Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. J. Virol. 2006, 80:6093-6105.
74. Sturniolo T., Bono E., Ding J., Raddrizzani L., Tuereci O., Sahin U., Braxenthaler M., Gallazzi F., Protti M.P., Sinigaglia F., Hammer J. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat. Biotechnol. 1999, 17:555-561.
75. Trkola A., Dragic T., Arthos J., Binley J.M., Olson W.C., Allaway G.P., Cheng-Mayer C., Robinson J., Maddon P.J., Moore J.P. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996, 384:184-187.
76. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., Lehrman J.K., Priddy F.H., Olsen O.A., Frey S.M., Hammond P.W., Miiro G., Serwanga J., Pozniak A., McPhee D., Manigart O., Mwananyanda L., Karita E., Inwoley A., Jaoko W., Dehovitz J., Bekker L.G., Pitisuttithum P., Paris R., Allen S., Kaminsky S., Zamb T., Moyle M., Koff W.C., Poignard P., Burton D.R. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009.
77. Wang S., Pal R., Mascola J.R., Chou T.H., Mboudjeka I., Shen S., Liu Q., Whitney S., Keen T., Nair B.C., Kalyanaraman V.S., Markham P., Lu S. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 2006, 350:34-47.
78. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
79. Wu L., Yang Z.Y., Xu L., Welcher B., Winfrey S., Shao Y., Mascola J.R., Nabel G.J. Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope. Vaccine 2006, 24:4995-5002.
80. Wu X., Sambor A., Nason M.C., Yang Z.Y., Wu L., Zolla-Pazner S., Nabel G.J., Mascola J.R. Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses. Virology 2008, 380:285-295.
81. Yamamoto S., Kiyono H., Yamamoto M., Imaoka K., Fujihashi K., Van Ginkel F.W., Noda M., Takeda Y., McGhee J.R. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl Acad. Sci. USA 1997, 94:5267-5272.
82. Yang Z.Y., Chakrabarti B.K., Xu L., Welcher B., Kong W.P., Leung K., Panet A., Mascola J.R., Nabel G.J. Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope. J. Virol. 2004, 78:4029-4036.
83. Zhang R.G., Scott D.L., Westbrook M.L., Nance S., Spangler B.D., Shipley G.G., Westbrook E.M. The three-dimensional crystal structure of cholera toxin. J. Mol. Biol. 1995, 251:563-573.
84. Zolla-Pazner S. Improving on nature: focusing the immune response on the V3 loop. Hum. Antibodies 2005, 14:69-72.
85. Zolla-Pazner S., Cohen S., Pinter A., Krachmarov C., Wrin T., Wang S., Lu S. Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. Virology 2009, 392:82-93.
86. Zolla-Pazner S., Cohen S.S., Krachmarov C., Wang S., Pinter A., Lu S. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology 2008, 372:233-246.
87. Zolla-Pazner S., Zhong P., Revesz K., Volsky B., Williams C., Nyambi P., Gorny M.K. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1. AIDS Res. Hum. Retroviruses 2004, 20:1254-1258.